Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy

NCT07684950 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER_GOV

Sponsor class

Conditions

Mantle Cell Lymphoma (MCL)

Interventions

DRUG: Lisaftoclax
DRUG: Pirtobrutinib

Sponsor

Henan Cancer Hospital